CIViC Evidence Items
8 evidence items indexed
Evidence Level Distribution
CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).
AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale
Gene × Evidence Type
Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.
| Predictive | Diagnostic | Prognostic | Functional | Predispos. | Oncogenic | |
|---|---|---|---|---|---|---|
| BCR::ABL1 | 323 | 11 | ||||
| BRAF | 186 | 4 | 26 | 2 | 1 | |
| EGFR | 248 | 12 | 3 | 2 | ||
| EML4::ALK | 64 | |||||
| ERBB2 | 142 | 2 | ||||
| FLT3 | 55 | 2 | 21 | |||
| KIT | 102 | 3 | 7 | |||
| KRAS | 159 | 4 | 24 | 4 | ||
| PIK3CA | 156 | 16 | 4 | |||
| PTEN | 53 | 1 | 3 | 1 | 2 | 1 |
| TP53 | 52 | 40 | 100 | 2 | ||
| VHL | 5 | 2 | 3 | 635 | 15 |
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
| Level | Gene | Variant | Type | Direction | Significance | Disease | Drugs | Source |
|---|---|---|---|---|---|---|---|---|
| B | SF3B1 | Mutation | Prognostic | Supports | Poor Outcome | Chronic Lymphocytic Leukemia | Baliakas et al., 2015 | |
| A | SF3B1 | Mutation | Prognostic | Supports | Poor Outcome | Chronic Lymphocytic Leukemia | Nadeu et al., 2016 | |
| B | SF3B1 | Mutation | Prognostic | Supports | Poor Outcome | Chronic Lymphocytic Leukemia | Wan et al., 2013 | |
| B | SF3B1 | Mutation | Prognostic | Supports | Poor Outcome | Chronic Lymphocytic Leukemia | Oscier et al., 2013 | |
| B | SF3B1 | Mutation | Prognostic | Supports | Better Outcome | Myelodysplastic Syndrome | Papaemmanuil et al., 2011 | |
| D | SF3B1 | K700E | Predictive | Supports | Sensitivity/Response | Leukemia | Etoposide,Olaparib | Lappin et al., 2022 |
| D | SF3B1 | K700E | Predictive | Supports | Sensitivity/Response | Breast Cancer | Spliceostatin A | Maguire et al., 2015 |
| D | SF3B1 | K666N | Predictive | Supports | Sensitivity/Response | Breast Cancer | Spliceostatin A | Maguire et al., 2015 |